| Diabetes Mellitus, Non-Insulin-Dependent
Atorvaliq vs Kerendia
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Atorvaliq vs Kerendia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKerendia has a higher rate of injection site reactions vs Atorvaliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kerendia but not Atorvaliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Atorvaliq
Kerendia
At A Glance
Oral
Daily
HMG-CoA reductase inhibitor
Oral
Once daily
Mineralocorticoid receptor antagonist
Indications
- Coronary heart disease
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Hyperlipidemia
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Chronic kidney disease stage 5
- Myocardial Infarction
Dosing
Coronary heart disease, Diabetes Mellitus Non-Insulin-Dependent, Heart failure, Hyperlipidemia, Hypertriglyceridemia 10 or 20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily.
Hypercholesterolemia, Familial (HeFH, pediatric >= 10 years) 10 mg once daily orally on an empty stomach; dosage range 10-20 mg once daily.
Hypercholesterolemia, Familial (HoFH, pediatric >= 10 years) 10-20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily.
Chronic Kidney Diseases, Diabetes Mellitus, Non-Insulin-Dependent Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg once daily, adjusted after 4 weeks based on serum potassium levels.
Heart failure Starting dose 10 mg or 20 mg orally once daily based on eGFR and serum potassium; target dose 20 mg or 40 mg once daily based on eGFR at initiation, adjusted after 4 weeks.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipients in ATORVALIQ
- Hypersensitivity to any component of Kerendia
- Concomitant treatment with strong CYP3A4 inhibitors
- Adrenal insufficiency
Adverse Reactions
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Most common (>=10%) hyperkalemia
Serious hyperkalemia requiring hospitalization, renal impairment, acute kidney injury, renal failure
Postmarketing angioedema, rash, urticaria
Pharmacology
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor; it lowers plasma cholesterol and LDL levels by inhibiting hepatic cholesterol synthesis and increasing hepatic LDL receptor expression.
Finerenone is a nonsteroidal, selective mineralocorticoid receptor (MR) antagonist that blocks MR-mediated sodium reabsorption and MR overactivation in epithelial (kidney) and nonepithelial (heart, blood vessels) tissues; it has high potency and selectivity for the MR with no relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Atorvaliq.
Kerendia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
No coverage data available for Atorvaliq.
Kerendia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
No coverage data available for Atorvaliq.
Kerendia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Atorvaliq.
$0/fillfill
Bayer US Patient Assistance Foundation - KerendiaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AtorvaliqView full Atorvaliq profile
KerendiaView full Kerendia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.